Citadel Advisors’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $37.1M | Sell |
951,515
-310,706
| -25% | -$10M | ﹤0.01% | 1864 |
|
|
2026
Q1 | $41.1M | Sell |
1,262,221
-470,200
| -27% | -$15.1M | 0.01% | 1545 |
|
|
2025
Q4 | $60.9M | Sell |
1,732,421
-165,921
| -9% | -$5.88M | 0.01% | 1248 |
|
|
2025
Q3 | $49.9M | Buy |
1,898,342
+1,025,367
| +117% | +$30.6M | 0.01% | 1377 |
|
|
2025
Q2 | $23.1M | Sell |
872,975
-778,115
| -47% | -$20.5M | ﹤0.01% | 1978 |
|
|
2025
Q1 | $39.9M | Buy |
1,651,090
+166,011
| +11% | +$5.25M | 0.01% | 1350 |
|
|
2024
Q4 | $59.8M | Buy |
1,485,079
+12,403
| +0.8% | +$707K | 0.01% | 1126 |
|
|
2024
Q3 | $93.2M | Buy |
1,472,676
+1,006,198
| +216% | +$59M | 0.02% | 739 |
|
|
2024
Q2 | $24.7M | Sell |
466,478
-435,271
| -48% | -$28.5M | 0.01% | 1782 |
|
|
2024
Q1 | $73.9M | Buy |
901,749
+830,182
| +1,160% | +$36.9M | 0.01% | 932 |
|
|
2023
Q4 | $1.33M | Buy |
+71,567
| New | +$936K | ﹤0.01% | 6105 |
|
|
2023
Q3 | – | Sell |
-89,717
| Closed | -$1.28M | – | 15194 |
|
|
2023
Q2 | $1.45M | Sell |
89,717
-59,475
| -40% | -$1.25M | ﹤0.01% | 5732 |
|
|
2023
Q1 | $2.48M | Buy |
149,192
+125,236
| +523% | +$1.29M | ﹤0.01% | 4970 |
|
|
2022
Q4 | $225K | Sell |
23,956
-28,291
| -54% | -$126K | ﹤0.01% | 9906 |
|
|
2022
Q3 | $143K | Sell |
52,247
-67,603
| -56% | -$221K | ﹤0.01% | 10762 |
|
|
2022
Q2 | $347K | Sell |
119,850
-491,795
| -80% | -$1.22M | ﹤0.01% | 9487 |
|
|
2022
Q1 | $1.83M | Buy |
611,645
+348,646
| +133% | +$1.25M | ﹤0.01% | 6277 |
|
|
2021
Q4 | $1.21M | Buy |
262,999
+138,954
| +112% | +$779K | ﹤0.01% | 7479 |
|
|
2021
Q3 | $779K | Sell |
124,045
-59,285
| -32% | -$366K | ﹤0.01% | 8775 |
|
|
2021
Q2 | $1.1M | Buy |
183,330
+111,631
| +156% | +$663K | ﹤0.01% | 8123 |
|
|
2021
Q1 | $454K | Sell |
71,699
-192,071
| -73% | -$1.35M | ﹤0.01% | 9882 |
|
|
2020
Q4 | $1.49M | Buy |
263,770
+132,536
| +101% | +$803K | ﹤0.01% | 5981 |
|
|
2020
Q3 | $763K | Buy |
131,234
+40,426
| +45% | +$278K | ﹤0.01% | 6535 |
|
|
2020
Q2 | $655K | Buy |
90,808
+69,600
| +328% | +$462K | ﹤0.01% | 6588 |
|
|
2020
Q1 | $99K | Buy |
+21,208
| New | +$130K | ﹤0.01% | 8641 |
|
|
2019
Q3 | – | Sell |
-37,111
| Closed | -$276K | – | 9798 |
|
|
2019
Q2 | $308K | Sell |
37,111
-1,036,463
| -97% | -$8.86M | ﹤0.01% | 7548 |
|
|
2019
Q1 | $10.7M | Buy |
1,073,574
+76,029
| +8% | +$636K | 0.01% | 1988 |
|
|
2018
Q4 | $7.63M | Buy |
997,545
+47,844
| +5% | +$572K | ﹤0.01% | 2215 |
|
|
2018
Q3 | $16.5M | Buy |
949,701
+506,430
| +114% | +$6.03M | 0.01% | 1568 |
|
|
2018
Q2 | $4.21M | Buy |
443,271
+428,296
| +2,860% | +$2.85M | ﹤0.01% | 2993 |
|
|
2018
Q1 | $65K | Buy |
+14,975
| New | +$82.8K | ﹤0.01% | 7851 |
|
|
2017
Q4 | – | Sell |
-56,461
| Closed | -$108K | – | 8472 |
|
|
2017
Q3 | $108K | Buy |
+56,461
| New | +$64.1K | ﹤0.01% | 7007 |
|
|
2016
Q3 | – | Sell |
-16,624
| Closed | -$21K | – | 7825 |
|
|
2016
Q2 | $21K | Buy |
16,624
+3,580
| +27% | +$4.72K | ﹤0.01% | 6590 |
|
|
2016
Q1 | $19K | Buy |
+13,044
| New | +$26.2K | ﹤0.01% | 6481 |
|
Other funds holding VKTX
Citadel Advisors's VKTX Position: Q2 2026 in Review
Citadel Advisors reduced its Viking Therapeutics (VKTX) stake by 25% in Q2 2026, selling an estimated $10M and leaving 951,515 shares worth $37.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1864.
Citadel Advisors first reported a position in VKTX in Q1 2016 and has held it in 34 quarters since. The position peaked at $93.2M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- Citadel Advisors held 951,515 shares of Viking Therapeutics worth $37.1M as of Q2 2026.
- Citadel Advisors sold 310,706 Viking Therapeutics shares in Q2 2026, an estimated $10M.
- Viking Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #1864 holding.
- Citadel Advisors first reported a position in Viking Therapeutics in Q1 2016 and has held it in 34 quarters since.
- Citadel Advisors's Viking Therapeutics position peaked at $93.2M in Q3 2024.
- 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.